Skip to main content

Precision Medicine in Neuroscience: Tools, Translation, and Implementation: A Workshop

In progress

Precision medicine approaches are rapidly transforming neuroscience, driven by advances in genetics, neuroimaging, biomarkers, and data science. These tools enable more refined disease classification, improved diagnosis, and treatments tailored to individual patients across neurological and psychiatric disorders. However, challenges remain in translating these advances into routine research and clinical practice. On March 4–5, the National Academies’ Forum on Neuroscience and Nervous System Disorders, in collaboration with the Forum on Drug Discovery, Development, and Translation and the Roundtable on Genomics and Precision Health, will host a workshop exploring opportunities, challenges, and strategies for integrating precision medicine into neuroscience research and care.

Description

A planning committee of the National Academies of Sciences, Engineering, and Medicine will host a 1.5-day public workshop to examine opportunities and challenges in applying precision medicine approaches to understanding and treating brain disorders. The workshop will bring together experts and stakeholders from across sectors and disciplines to explore how advances in biology, data science, drug development, and clinical practice are shaping the future of individualized care for neurological and psychiatric conditions.
Invited presentations and discussions may:

  • Highlight case examples where precision medicine approaches have informed research, diagnosis, treatment, and disease reclassification in neuroscience.
  • Examine emerging tools and technologies (including biomarkers, multi-omics, computational psychiatry, and artificial intelligence) and their applications across neuroscience research and clinical care.
  • Consider barriers and opportunities for implementation, including provider education, patient engagement, payer and regulatory models, data privacy, clinical integration, and potential risks.
  • Explore models for academia-industry-regulatory collaboration to de-risk precision drug development in neuroscience.
  • Explore cross-disease and holistic frameworks, including how precision medicine approaches can address comorbidities and support a broader brain health model.

A planning committee will develop the agenda for the workshop, select and invite speakers and discussants, and moderate the discussions. Following the workshop, a proceedings of the presentations and discussions will be prepared by a designated rapporteur in accordance with institutional guidelines.

Contributors

Committee

Rosa Canet-Avilés

Co-Chair

Gayle Wittenberg

Co-Chair

Linda S. Brady

Member

Laura Bustamante

Member

Brian Fiske

Member

Magali Haas

Member

Julie Harris

Member

Steven E. Hyman

Member

Michael Irizarry

Member

Bruce Korf

Member

Dimitri Krainc

Member

Sponsors

23andMe

Acadia Pharmaceuticals

All of Us Research Program

Alzheimer's Association

American Academy of Nursing

American Brain Coalition

American College of Medical Genetics and Genomics

American College of Neuropsychopharmacology

American Medical Association

American Neurological Association

American Society of Clinical Oncology

American Society of Human Genetics

Amgen Inc

Apricity Health, Inc.

Association for Molecular Pathology

Association of American Medical Colleges

Biogen

BrightFocus Foundation

Burroughs Wellcome Fund

California Institute for Regenerative Medicine

Cohen Veterans Bioscience

College of American Pathologists

Critical Path Institute

Dana Foundation

Department of Veterans Affairs

Eisai

Eli Lilly and Company

FasterCures, Milken Institute

Food and Drug Administration

Foundation for the National Institutes of Health

Gatsby Charitable Foundation

Geisinger Health

Genome Medical

Harmony Biosciences

Health Resources and Services Administration

Huo Family Foundation

Illumina Inc.

Janssen Research & Development, LLC

Johnson & Johnson

Kaiser Permanente

Medable

Merck & Co., Inc.

Michael J. Fox Foundation for Parkinson's Research

Myriad Genetics

National Cancer Institute

National Center for Complementary and Integrative Health

National Eye Institute

National Human Genome Research Institute

National Institute of Environmental Health Sciences

National Institute of Mental Health

National Institute of Neurological Disorders and Stroke

National Institute of Nursing Research

National Institute on Aging

National Institute on Alcohol Abuse and Alcoholism

National Institute on Drug Abuse

National Institutes of Health BRAIN Initiative

National Multiple Sclerosis Society

National Science Foundation

National Society of Genetic Counselors, Inc

New England Journal of Medicine

One Mind

Paul G. Allen Frontiers Group

Regeneron Pharmaceuticals

Sanofi

Simons Foundation

The Jackson Laboratory (JAX)

Tufts Center for the Study of Drug Development

University of California, San Francisco

University of Vermont Health Network Medical Group

Staff

Sheena Posey Norris

Lead

Ashley Pitt

Sarah Beachy

Carolyn Shore

Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.